Roche Acquires Zealand Pharma Obesity Drug
This is a news story, published by CNBC, that relates primarily to Pharma news.
Pharma news
For more Pharma news, you can click here:
more Pharma newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Swiss pharmaceutical giant Roche. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Zealand Pharma news, Zealand Pharma CEO news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Danish biotech Zealand PharmaCNBC
•Health
Health
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

74% Informative
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma 's obesity drug candidate.
Shares of Zealand Pharma jumped as much as 29% shortly after the announcement, while Roche added 4.6% .
Deal will see the two companies co-develop and co-commercialize petrelintide as a standalone therapy.
VR Score
81
Informative language
86
Neutral language
42
Article tone
formal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links